N/A
Manufactured by Haleon US Holdings LLC
26,055 FDA adverse event reports analyzed
Last updated: 2026-04-14
DOCOSANOL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Haleon US Holdings LLC. The most commonly reported adverse reactions for DOCOSANOL include DRUG INEFFECTIVE, ORAL HERPES, CONDITION AGGRAVATED, DRUG ADMINISTRATION ERROR, INCORRECT DRUG ADMINISTRATION DURATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DOCOSANOL.
Out of 14,469 classified reports for DOCOSANOL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 26,055 FDA FAERS reports that mention DOCOSANOL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, ORAL HERPES, CONDITION AGGRAVATED, DRUG ADMINISTRATION ERROR, INCORRECT DRUG ADMINISTRATION DURATION, HERPES SIMPLEX. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Haleon US Holdings LLC in connection with DOCOSANOL. Always verify the specific product and NDC with your pharmacist.